Collectively, these findings suggest that elevated PDGFRA expression in liver cancer tissues is associated with reduced sensitivity to lenvatinib therapy, underscoring the potential of PDGFRA expression as a predictive biomarker for the therapeutic response to lenvatinib in HCC patients. This evidence concerns the gene PDGFRA and hepatocellular carcinoma.